ArticleOncoTargets and therapy2019

Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report.

Yan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.